A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib

Suspected metastatic site lesions that are poorly differentiated present a diagnostic challenge when morphologic and immunohistochemical profiling cannot establish the primary tumor site. Here we present a patient diagnosed with both a malignant neoplasm in the lung and a right upper extremity (RUE)...

Full description

Bibliographic Details
Main Authors: Jon H. Chung, Siraj M. Ali, Jenni Davis, Karl Robstad, Richard McNally, Laurie M. Gay, Rachel L. Erlich, Norma A. Palma, Phil J. Stephens, Vincent A. Miller, Alfonso Cutugno, Jeffrey S. Ross
Format: Article
Language:English
Published: Karger Publishers 2014-09-01
Series:Case Reports in Oncology
Subjects:
Crizotinib
ALK
Unknown primary tumor site
Poorly differentiated lung neoplasm
Online Access:http://www.karger.com/Article/FullText/367780

Internet

http://www.karger.com/Article/FullText/367780

Similar Items